Get App

Roche says Ocrevus drug reduces need for walking aids for MS patients

There was also a 29% reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.
  • Updated On Oct 13, 2021 at 04:07 PM IST
ZURICH: Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday.

There was a 35% reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29% reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.

  • Published On Oct 13, 2021 at 04:05 PM IST

Comments

comment
What are your thoughts?
Comment Now Read Comment (1)

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!